ScrutarSign up free

NVAX SEC Filings

SEC filings for NVAX. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.

All10-K10-Q8-KProxyForm 413D/GLast 12 months
FormFiledAccession
8-KAINovavax reported Q3 2026 total revenue of $68 million (down 3% from $70 million) and a net loss of $31 million, versus a $202 million loss a year earlier.Nov 5, 2026EDGAR
10-QNov 5, 2026EDGAR
8-KOct 29, 2026EDGAR
SC 13GHimanshu H. Shah and 2 other reporting personsOct 16, 2026EDGAR
SC 13D/AamendedHimanshu H. Shah and 2 other reporting personsOct 16, 2026EDGAR
SC 13GSTATE STREET CORPORATIONAug 7, 2026EDGAR
10-QAug 6, 2026EDGAR
8-KAug 6, 2026EDGAR
4Rodgers Richard JJun 23, 2026EDGAR
4King Rachel K.Jun 23, 2026EDGAR
4DOUGLAS RICHARDJun 23, 2026EDGAR
4MCGLYNN MARGARET GJun 23, 2026EDGAR
4MOTT DAVID MJun 23, 2026EDGAR
4Alton Gregg HJun 23, 2026EDGAR
8-KAINovavax held its Annual Meeting on June 18, 2026, with 99,118,766 of 164,427,429 outstanding shares (about 60.3%) present.Jun 23, 2026EDGAR
SC 13D/AamendedHimanshu H. Shah and 2 other reporting personsMay 15, 2026EDGAR
8-KAINovavax reported Q1 2026 total revenue of $140 million, down 79% from $667 million in Q1 2025, which included $603 million of non-cash revenue from the close-out of two APAs.May 6, 2026EDGAR
10-QMay 6, 2026EDGAR
SC 13GVanguard Capital ManagementApr 30, 2026EDGAR
4Newton Charles W.Apr 28, 2026EDGAR
SC 13G/AamendedBANK OF AMERICA CORP /DE/Apr 27, 2026EDGAR
SC 13D/AamendedHimanshu H. Shah and 2 other reporting personsApr 8, 2026EDGAR
SC 13G/AamendedThe Vanguard GroupMar 27, 2026EDGAR
4Shiver John W.Mar 12, 2026EDGAR
4Kelly James PatrickEVP, CFO and TreasurerMar 9, 2026EDGAR
4Kelly James PatrickEVP, CFO and TreasurerMar 5, 2026EDGAR
4Jacobs John CPresident and CEOMar 5, 2026EDGAR
4O'Hara ElaineEVP, Chief Strategy OfficerMar 5, 2026EDGAR
4Casey Mark JEVP, Chief Legal OfficerMar 5, 2026EDGAR
4Draghia-Akli RuxandraEVP, Research & DevelopmentMar 5, 2026EDGAR
4Jacobs John CPresident and CEOMar 4, 2026EDGAR
4Kelly James PatrickEVP, CFO and TreasurerMar 4, 2026EDGAR
4O'Hara ElaineEVP, Chief Strategy OfficerMar 4, 2026EDGAR
4Casey Mark JEVP, Chief Legal OfficerMar 4, 2026EDGAR
10-KAINovavax reports a sharp swing to $440.3M net income on one-time APA termination revenue, steep cost cuts, and new Pfizer and Sanofi partnership milestones, framed optimistically.Feb 26, 2026EDGAR
8-KFeb 26, 2026EDGAR
SC 13GBANK OF AMERICA CORP /DE/Feb 11, 2026EDGAR
SC 13GSTATE STREET CORPORATIONFeb 9, 2026EDGAR
4Jacobs John CPresident and CEOJan 27, 2026EDGAR
8-KJan 20, 2026EDGAR
8-KAINovavax furnished an investor presentation for the 44th J.P.Jan 12, 2026EDGAR
4Casey Mark JEVP, Chief Legal OfficerDec 15, 2025EDGAR
4Draghia-Akli RuxandraSection 16Nov 13, 2025EDGAR
SC 13D/AamendedHimanshu H. Shah and 2 other reporting personsNov 12, 2025EDGAR
8-KNov 6, 2025EDGAR
10-QAIMixed tone.Nov 6, 2025EDGAR

SEC filings for companies related to NVAX

MRNAModerna, Inc.PFEPFIZER INCMRKMerck & Co., Inc.

Never miss a NVAX filing.

Get an email when NVAX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Source: SEC EDGAR.